We distribute our research widely to institutional and retail investors through various channels, including our proprietary database, website, and other platforms (such as Bloomberg, Thomson Reuters and Factset).

We are fully MiFID II compliant. Our research is paid for by our corporate clients, and we do not carry out any execution business.

Published reports can be obtained by searching our Research Library below, or directly from the relevant Company Pages.

Advanced search
Date range (dd-mm-yyyy)

Allergy Therapeutics

G309 exploratory grass trial on course for H221 read-out

Lighthouse | 06 May 2021

Futura Medical

MED3000 receives CE Mark as a Class II(b) device

Lighthouse | 30 April 2021

MaxCyte

Catching an unbroken wave

Update | 27 April 2021

Futura Medical

FY21 is set to be a year of execution

Update | 14 April 2021

HUTCHMED

Baring Private Equity Asia invests $100m

Lighthouse | 08 April 2021

Nexstim

Rights issue 178% oversubscribed

Lighthouse | 08 April 2021

HUTCHMED

Breaking new ground in China and globally

Outlook | 30 March 2021

Futura Medical

EU Notified Body recommends MED3000 approval

Lighthouse | 19 March 2021

Nexstim

Subscription rights issue of €6.6m at €0.03 per share

Lighthouse | 08 March 2021

Hutchison China MediTech

Transitioning to a global oncology player

Lighthouse | 05 March 2021
< 3 4 5 6 7 8 9 10 11 12 >
314 results found.